This website is for informational purposes only and does not constitute medical advice. Read disclaimer
Nafarelin
A potent synthetic GnRH agonist administered as a nasal spray, primarily used for the treatment of endometriosis and central precocious puberty.
Overview
Nafarelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that incorporates a 3-(2-naphthyl)-D-alanine substitution at position 6, making it approximately 200 times more potent than native GnRH. Developed by Syntex (now Roche) and first approved by the FDA in 1990, nafarelin is notable for being formulated as an intranasal spray (Synarel), providing a needle-free alternative to injectable GnRH agonists.
The intranasal route of administration sets nafarelin apart from most other GnRH agonists in clinical use. The nasal spray formulation achieves approximately 2-3% bioavailability through the nasal mucosa, which is sufficient for clinical efficacy given the high potency of the compound. This non-invasive delivery method can improve patient acceptance and compliance, particularly in pediatric patients being treated for central precocious puberty.
Like other GnRH agonists, nafarelin induces initial pituitary stimulation followed by receptor downregulation and sustained suppression of gonadotropin and sex steroid production. The onset of suppression typically occurs within 2-4 weeks of initiating therapy. For endometriosis, nafarelin reduces estrogen levels to the menopausal range, leading to atrophy of endometriotic implants and significant pain relief.
Clinical trials have demonstrated nafarelin's efficacy is comparable to other GnRH agonists and to surgical treatment for endometriosis-related pain. In central precocious puberty, nafarelin nasal spray provides effective pubertal suppression and has been shown to preserve adult height potential. The drug requires twice-daily dosing, which can be a disadvantage compared to monthly or three-monthly depot injections of other GnRH agonists.